The prevalence of pathogenic KRAS or GNAS variants is high in mucinous neoplasm (approximately 2/3 of mucinous neoplasms contain a pathogenic variant of either KRAS, GNAS or both 38), making KRAS and GNAS variants reliable molecular markers. Here, KRAS is linked to mucinous neoplasm.